
Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …
New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …
Sanofi subsidiary Genzyme moved a crucial step closer to resolving its long-standing manufacturing problems after the European Medicines Agency gave …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

